Blueprint Medicines Secures $50 Million in Series C Financing

Proceeds to support continued advancement of highly selective kinase inhibitors to genomically defined cancers, including first-in-class FGFR4 and KIT Exon 17 inhibitors

Investor syndicate includes leading public healthcare funds

CAMBRIDGE, Mass., No...
Biopharmaceuticals, Venture Capital
Blueprint Medicines